Metabolic Dysfunction-Associated Fatty Liver Disease and Fibrosis Status in Patients with Type 2 Diabetes Treated at Internal Medicine Clinics: Türkiye DAHUDER Awareness of Fatty Liver Disease (TR-DAFLD) Study

Basit Öğe Kaydı
dc.authoridKoker, Gokhan/0000-0003-1745-8002
dc.authoridKIR, Seher/0000-0003-2835-1745
dc.authoriduyar, seyit/0000-0002-2435-8248
dc.contributor.authorSahinturk, Yasin
dc.contributor.authorKoker, Gokhan
dc.contributor.authorKoca, Nizameddin
dc.contributor.authorSumbul, Hilmi Erdem
dc.contributor.authorDemir, Ismail
dc.contributor.authorKeskin, Havva
dc.contributor.authorYaylaci, Selcuk
dc.date.accessioned2025-02-22T14:08:37Z
dc.date.available2025-02-22T14:08:37Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/Aims: This awareness study aimed to determine the ultrasound (US) examination rates in relation to US-confirmed metabolic dysfunction-associated fatty liver disease (MAFLD) diagnosis in internal medicine outpatients with type 2 diabetes (T2D) across T & uuml;rkiye. Materials and Methods: A total of 6283 T2D patients were included in this multicenter retrospective cohort study conducted at 17 internal medicine clinics across T & uuml;rkiye. The presence and indications for US performed within the last 3 years were recorded along with US-confirmed MAFLD rates, laboratory findings on the day of US, and referral rates. Fibrosis-4 (FIB-4) index was calculated to estimate the risk of advanced liver fibrosis (FIB-4 index >= 1.3). Results: Overall, 1731 (27.6%) of 6283 patients had US examination, which revealed MAFLD diagnosis in 69.9% of cases. In addition, 24.4% of patients with US-confirmed MAFLD were at risk of advanced fibrosis (FIB-4 index >= 1.3), and the referral rate was 15.5%. Conclusion: In conclusion, our findings emphasize an insufficient MAFLD awareness among clinicians and the likelihood of most of T2D patients to be at risk of living with an unknown status regarding their MAFLD and advanced fibrosis risk.en_US
dc.identifier.doi10.5152/tjg.2024.24045
dc.identifier.issn2148-5607
dc.identifier.issue8en_US
dc.identifier.pmid39150440en_US
dc.identifier.scopus2-s2.0-85201444866en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2024.24045
dc.identifier.urihttps://hdl.handle.net/11468/29510
dc.identifier.volume35en_US
dc.identifier.wosWOS:001318111800007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectType 2 diabetesen_US
dc.subjectmetabolic dysfunction-associated fatty liver diseaseen_US
dc.subjectultrasound imagingen_US
dc.subjectfibrosis indexen_US
dc.subjectawarenessen_US
dc.subjectMASLDen_US
dc.titleMetabolic Dysfunction-Associated Fatty Liver Disease and Fibrosis Status in Patients with Type 2 Diabetes Treated at Internal Medicine Clinics: Türkiye DAHUDER Awareness of Fatty Liver Disease (TR-DAFLD) Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu